Tarsus Pharmaceuticals In... (TARS)
Tarsus Pharmaceuticals Inc. (TARS) Stock Price, Analysis & Data
| Bid | 50.72 |
| Market Cap | 3.04B |
| Revenue (ttm) | 606.33M |
| Net Income (ttm) | -46.48M |
| Beta | 0.51 |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | n/a |
| Forward PE | 29.76 |
| P/B (ttm) | 8.64 |
| P/S (ttm) | 5.01 |
| Earnings Date | Nov 4, 2026 |
| Ask | 90.88 |
| Volume | 423,303 |
| Avg. Volume (20D) | 963,374 |
| Open | 68.82 |
| Previous Close | 68.88 |
| Day's Range | 67.61 - 69.70 |
| 52-Week Range | 48.20 - 85.25 |
| Analyst | Strong Buy |
| Price Target | 99 (43.06%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal h...
Financial Performance
In 2025, Tarsus Pharmaceuticals's revenue was 451.36M, an increase of 146.71% compared to the previous year's 182.95M. Earnings were -66.42M, a decrease of -42.52%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for TARS stock is "Strong Buy". The 12-month stock price forecast is 99, which is upside of 43.06% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
